BCT vs. MBX, SVA, EMH, PMN, DMT, HBP, GSD, IBT, AEZS, and LTY
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Microbix Biosystems (MBX), Sernova (SVA), Emerald Health Therapeutics (EMH), ProMIS Neurosciences (PMN), Small Pharma (DMT), Helix BioPharma (HBP), Devonian Health Group (GSD), IBEX Technologies (IBT), Aeterna Zentaris (AEZS), and Liberty Biopharma (LTY). These companies are all part of the "biotechnology" industry.
BriaCell Therapeutics vs.
BriaCell Therapeutics (TSE:BCT) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
15.0% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Microbix Biosystems shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Comparatively, 14.0% of Microbix Biosystems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Microbix Biosystems has a net margin of 13.86% compared to BriaCell Therapeutics' net margin of 0.00%. BriaCell Therapeutics' return on equity of 536.29% beat Microbix Biosystems' return on equity.
Microbix Biosystems has higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.
BriaCell Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, Microbix Biosystems has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
In the previous week, Microbix Biosystems had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Microbix Biosystems and 0 mentions for BriaCell Therapeutics. Microbix Biosystems' average media sentiment score of 1.03 beat BriaCell Therapeutics' score of 0.00 indicating that Microbix Biosystems is being referred to more favorably in the news media.
Microbix Biosystems received 69 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 70.71% of users gave Microbix Biosystems an outperform vote.
Summary
Microbix Biosystems beats BriaCell Therapeutics on 10 of the 14 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
This page (TSE:BCT) was last updated on 4/3/2025 by MarketBeat.com Staff
Buy BCT Stock Free BCT Stock Alerts